{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:09:18Z","timestamp":1779527358308,"version":"3.53.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00855-0","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T17:51:07Z","timestamp":1776189067000},"page":"799-812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting"],"prefix":"10.1007","volume":"13","author":[{"given":"Peter C.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Kadakia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"5","key":"855_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"K Almutairi","year":"2021","unstructured":"Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int. 2021;41(5):863\u201377. https:\/\/doi.org\/10.1007\/s00296-020-04731-0.","journal-title":"Rheumatol Int"},{"issue":"10055","key":"855_CR2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8.","journal-title":"Lancet"},{"issue":"1","key":"855_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001. https:\/\/doi.org\/10.1038\/nrdp.2018.1.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"855_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"855_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924\u201339. https:\/\/doi.org\/10.1002\/acr.24596.","journal-title":"Arthritis Care Res"},{"key":"855_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519\u201331. https:\/\/doi.org\/10.2147\/JIR.S219586.","journal-title":"J Inflamm Res"},{"issue":"10139","key":"855_CR7","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2018;391(10139):2503\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(18)31115-2.","journal-title":"The Lancet"},{"issue":"3","key":"855_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559\u201370. https:\/\/doi.org\/10.1002\/art.37816.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"855_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506\u201317. https:\/\/doi.org\/10.1002\/art.39953.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"855_CR10","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019;78(10):1305\u201319. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215164.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"855_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","volume":"20","author":"Z Szekanecz","year":"2024","unstructured":"Szekanecz Z, Buch MH, Charles-Schoeman C, et al. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol. 2024;20(2):101\u201315. https:\/\/doi.org\/10.1038\/s41584-023-01062-9.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"855_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","volume":"20","author":"A Virtanen","year":"2024","unstructured":"Virtanen A, Spinelli FR, Telliez JB, O\u2019Shea JJ, Silvennoinen O, Gadina M. JAK inhibitor selectivity: new opportunities, better drugs? Nat Rev Rheumatol. 2024;20(10):649\u201365. https:\/\/doi.org\/10.1038\/s41584-024-01153-1.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"855_CR13","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1007\/s12325-020-01303-3","volume":"37","author":"J Pope","year":"2020","unstructured":"Pope J, Sawant R, Tundia N, et al. Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. Adv Ther. 2020;37(5):2356\u201372. https:\/\/doi.org\/10.1007\/s12325-020-01303-3.","journal-title":"Adv Ther"},{"issue":"1","key":"855_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40744-020-00257-w","volume":"8","author":"CJ Edwards","year":"2021","unstructured":"Edwards CJ, Sawant R, Garg V, Du EX, Friedman A, Betts KA. A matching-adjusted indirect comparison of upadacitinib versus tofacitinib in adults with moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2021;8(1):167\u201381. https:\/\/doi.org\/10.1007\/s40744-020-00257-w.","journal-title":"Rheumatol Ther"},{"key":"855_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1387585","volume":"15","author":"W Cai","year":"2024","unstructured":"Cai W, Tong R, Sun Y, Yao Y, Zhang J. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2024;15:1387585. https:\/\/doi.org\/10.3389\/fphar.2024.1387585.","journal-title":"Front Pharmacol"},{"issue":"10","key":"855_CR16","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1007\/s12325-023-02619-6","volume":"40","author":"M Bergman","year":"2023","unstructured":"Bergman M, Chen N, Thielen R, Zueger P. One-year medication adherence and persistence in rheumatoid arthritis in clinical practice: a retrospective analysis of upadacitinib, adalimumab, baricitinib, and tofacitinib. Adv Ther. 2023;40(10):4493\u2013503. https:\/\/doi.org\/10.1007\/s12325-023-02619-6.","journal-title":"Adv Ther"},{"key":"855_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152314","volume":"64","author":"L Scheepers","year":"2024","unstructured":"Scheepers L, Yang Y, Chen YL, Jones G. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study. Semin Arthritis Rheum. 2024;64:152314. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152314.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"855_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40744-024-00736-4","volume":"12","author":"P Youssef","year":"2025","unstructured":"Youssef P, Ciciriello S, Tahir T, et al. Real-world persistence and effectiveness of upadacitinib versus other Janus kinase inhibitors and tumor necrosis factor inhibitors in Australian patients with rheumatoid arthritis. Rheumatol Ther. 2025;12(1):173\u2013202. https:\/\/doi.org\/10.1007\/s40744-024-00736-4.","journal-title":"Rheumatol Ther"},{"issue":"9","key":"855_CR19","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.55563\/clinexprheumatol\/n0kjax","volume":"42","author":"S Ciciriello","year":"2024","unstructured":"Ciciriello S, Littlejohn GO, Treuer T, et al. Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset. Clin Exp Rheumatol. 2024;42(9):1763\u201372. https:\/\/doi.org\/10.55563\/clinexprheumatol\/n0kjax.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"855_CR20","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1093\/rheumatology\/kead543","volume":"63","author":"S Hayashi","year":"2024","unstructured":"Hayashi S, Tachibana S, Maeda T, et al. Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Rheumatology Oxford. 2024;63(11):3033\u201341. https:\/\/doi.org\/10.1093\/rheumatology\/kead543.","journal-title":"Rheumatology Oxford"},{"issue":"1","key":"855_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04075-0","volume":"12","author":"K Ebina","year":"2022","unstructured":"Ebina K, Hirano T, Maeda Y, et al. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep. 2022;12(1):134. https:\/\/doi.org\/10.1038\/s41598-021-04075-0.","journal-title":"Sci Rep"},{"issue":"12","key":"855_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, de Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315. https:\/\/doi.org\/10.1080\/03007995.2023.2279679.","journal-title":"Curr Med Res Opin"},{"key":"855_CR23","unstructured":"AbbVie Receives FDA Approval of RINVOQTM (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis. AbbVie News Cent. https:\/\/news.abbvie.com\/2019-08-16-AbbVie-Receives-FDA-Approval-of-RINVOQ-TM-upadacitinib-an-Oral-JAK-Inhibitor-For-The-Treatment-of-Moderate-to-Severe-Rheumatoid-Arthritis. Accessed 2 Oct 2025."},{"key":"855_CR24","unstructured":"Summary Basis of Decision for Rinvoq. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/SBD00474. Accessed 2 Oct 2025"},{"issue":"6","key":"855_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40264-021-01067-x","volume":"44","author":"K Yamaoka","year":"2021","unstructured":"Yamaoka K, Tanaka Y, Kameda H, et al. The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan. Drug Saf. 2021;44(6):711\u201322. https:\/\/doi.org\/10.1007\/s40264-021-01067-x.","journal-title":"Drug Saf"},{"key":"855_CR26","unstructured":"Rinvoq | European Medicines Agency (EMA) 2019; https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq. Accessed 2 Oct 2025"},{"issue":"9","key":"855_CR27","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s12325-024-02948-0","volume":"41","author":"R Caporali","year":"2024","unstructured":"Caporali R, Kadakia A, Howell O, et al. A real-world comparison of clinical effectiveness in patients with rheumatoid arthritis treated with upadacitinib, tumor necrosis factor inhibitors, and other advanced therapies after switching from an initial tumor necrosis factor inhibitor. Adv Ther. 2024;41(9):3706\u201321. https:\/\/doi.org\/10.1007\/s12325-024-02948-0.","journal-title":"Adv Ther"},{"key":"855_CR28","unstructured":"2024 EPHMRA Code of Conduct Final. EphMRA Code Conduct. https:\/\/www.ephmra.org\/sites\/default\/files\/2024-09\/2024%20EPHMRA%20Code%20of%20Conduct%20Final.pdf. Accessed 10 Feb 2026"},{"key":"855_CR29","unstructured":"Summary of the HIPAA Privacy Rule. HHS Summ HIPAA Priv Rule. https:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf. Accessed 10 Feb 2026"},{"key":"855_CR30","unstructured":"Health Information Technology (HITECH). Health Information Technology Act. https:\/\/healthit.gov\/wp-content\/uploads\/2025\/06\/hitech_act_excerpt_from_arra_with_index.pdf. Accessed 10 Feb 2026"},{"key":"855_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/BTT.S474733","volume":"18","author":"P Santos-Moreno","year":"2024","unstructured":"Santos-Moreno P, Rodr\u00edguez-Vargas G-S, Rodr\u00edguez-Linares P, et al. Effectiveness and persistence of anti-TNF\u03b1 treatment in patients with rheumatoid arthritis \u2013 a 7-year real-world cohort study. Biol Targets Ther. 2024;18:339\u201347. https:\/\/doi.org\/10.2147\/BTT.S474733.","journal-title":"Biol Targets Ther"},{"issue":"8","key":"855_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105193","volume":"9","author":"A Fisher","year":"2014","unstructured":"Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman H, Dormuth CR. Comparative persistence of the TNF antagonists in rheumatoid arthritis \u2013 a population-based cohort study. PLoS ONE. 2014;9(8):e105193. https:\/\/doi.org\/10.1371\/journal.pone.0105193.","journal-title":"PLoS ONE"},{"issue":"10","key":"855_CR33","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1007\/s12325-023-02600-3","volume":"40","author":"J Dal\u00e9n","year":"2023","unstructured":"Dal\u00e9n J, Svedbom A, Hernlund E, Olofsson T, Black CM. Identifying predictors of first-line subcutaneous TNF-inhibitor persistence in patients with inflammatory arthritis: a decision tree analysis by indication. Adv Ther. 2023;40(10):4657\u201374. https:\/\/doi.org\/10.1007\/s12325-023-02600-3.","journal-title":"Adv Ther"},{"issue":"4","key":"855_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/acr2.11646","volume":"6","author":"C Edgerton","year":"2024","unstructured":"Edgerton C, Frick A, Helfgott S, et al. Real\u2010world treatment and care patterns in patients with rheumatoid arthritis initiating first\u2010line tumor necrosis factor inhibitor therapy in the United States. ACR Open Rheumatol. 2024;6(4):179\u201388. https:\/\/doi.org\/10.1002\/acr2.11646.","journal-title":"ACR Open Rheumatol"},{"key":"855_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/CEOR.S115706","volume":"8","author":"MM Bonafede","year":"2016","unstructured":"Bonafede MM, Curtis JR, McMorrow D, Mahajan P, Chen C-I. Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. Clin Outcomes Res CEOR. 2016;8:707\u201315. https:\/\/doi.org\/10.2147\/CEOR.S115706.","journal-title":"Clin Outcomes Res CEOR"},{"issue":"4","key":"855_CR36","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s40744-021-00357-1","volume":"8","author":"EA Holdsworth","year":"2021","unstructured":"Holdsworth EA, Donaghy B, Fox KM, Desai P, Collier DH, Furst DE. Biologic and targeted synthetic DMARD utilization in the United States: Adelphi Real World Disease Specific Programme for rheumatoid arthritis. Rheumatol Ther. 2021;8(4):1637\u201349. https:\/\/doi.org\/10.1007\/s40744-021-00357-1.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"855_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40744-020-00203-w","volume":"7","author":"E Sullivan","year":"2020","unstructured":"Sullivan E, Kershaw J, Blackburn S, Choi J, Curtis JR, Boklage S. Biologic disease-modifying antirheumatic drug prescription patterns for rheumatoid arthritis among United States physicians. Rheumatol Ther. 2020;7(2):383\u2013400. https:\/\/doi.org\/10.1007\/s40744-020-00203-w.","journal-title":"Rheumatol Ther"},{"key":"855_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221091450","volume":"14","author":"D-J Park","year":"2022","unstructured":"Park D-J, Choi S-E, Kang J-H, Shin K, Sung Y-K, Lee S-S. Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure. Ther Adv Musculoskelet Dis. 2022;14:1759720X221091450. https:\/\/doi.org\/10.1177\/1759720X221091450.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"855_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02744-7","volume":"24","author":"S Ochi","year":"2022","unstructured":"Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: From the FIRST Registry. Arthritis Res Ther. 2022;24(1):61. https:\/\/doi.org\/10.1186\/s13075-022-02744-7.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"855_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-2125-2","volume":"22","author":"T Takeuchi","year":"2020","unstructured":"Takeuchi T, Tanaka Y, Tanaka S, et al. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Res Ther. 2020;22(1):47. https:\/\/doi.org\/10.1186\/s13075-020-2125-2.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"855_CR41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81(3):335\u201343. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221276.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"855_CR42","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1007\/s12325-025-03328-y","volume":"42","author":"GR Burmester","year":"2025","unstructured":"Burmester GR, Deodhar A, Irvine AD, et al. Safety profile of upadacitinib: Descriptive analysis in over 27,000 patient-years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease. Adv Ther. 2025;42(10):5215\u201337. https:\/\/doi.org\/10.1007\/s12325-025-03328-y.","journal-title":"Adv Ther"},{"issue":"3","key":"855_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395","volume":"6","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6(3):e001395. https:\/\/doi.org\/10.1136\/rmdopen-2020-001395.","journal-title":"RMD Open"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00855-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00855-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00855-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:46:42Z","timestamp":1779526002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00855-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00855-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors. Peter C. Taylor: Research grants from: Alfasigma; consultancy fees from: AbbVie Inc., Eli Lilly, Fresenius, Alfasigma, Gilead, Janssen, Nordic, Takeda, and UCB; participation on a Data Safety Monitoring Board\/Advisory Board for Immunovant, Sanofi, and MoonLake. Aditi Kadakia: Employee of AbbVie, Inc., and may hold stock or options. Ana Romero: Employee of AbbVie, Inc., and may hold stock or options. Pankaj A. Patel: Employee of AbbVie, Inc., and may hold stock or options. Jack Milligan: Employee of Adelphi Real World, who acted as a consultant to AbbVie Inc. for this analysis and has no other conflicts of interest. Oliver Howell: Employee of Adelphi Real World, who acted as a consultant to AbbVie Inc. for this analysis and has no other conflicts of interest. Sophie Barlow: Employee of Adelphi Real World, who acted as a consultant to AbbVie Inc. for this analysis and has no other conflicts of interest. Roberto Caporali: Received speaker and\/or consultant fees from AbbVie Inc., Alfasigma, Accord, Celltrion, Eli Lilly, Fresenius, Galapagos, Janssen, MSD, Novartis, Pfizer, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Using a check box, patients provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated and de-identified before receipt. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association (EphMRA) guidelines [\n                      \n                      ], and therefore it does not require ethics committee approval. The research was submitted to the Institutional Review Board (IRB), study protocol number: Protocol #21-ADRW-104. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [\n                      \n                      ], Health Information Technology for Economic and Clinical Health Act legislation [\n                      \n                      ], and the 1964 Declaration of Helsinki and its later amendments. The US, Japan, and Canada are signatories to the EphMRA Code of Conduct.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}